Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.64 |
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371630 | 0.91 | MET (0.83) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL30314058 | 0.91 | MET (0.83) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL371934 | 0.90 | MET (1.00) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL19711758 | 0.87 | MET (0.62) | METPDGFRAKITKDRPDGFRB | |
| SCHEMBL12444758 | 0.84 | MET (0.89) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL371684 | 0.84 | MET (0.72) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL372754 | 0.82 | MET (0.70) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL371727 | 0.82 | MET (0.70) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL19711759 | 0.82 | MET (0.60) | METPDGFRAKITKDRPDGFRB | |
| SCHEMBL15338406 | 0.82 | MET (0.85) | METPDGFRAKITKDRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.